Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 10:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 7,363 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: NERVES Clear all
Completed No phase listed Observational

A Follow-up Study of Women Evaluated and Treated for Infertility

NCT00342446
View directory record Official record
Conditions
Ovarian Cancer, Breast Cancer, Endometrial Cancer, Thyroid Cancer, Colorectal Cancer, Melanoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
44 Years to 88 Years · Female only
Enrollment
12,193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Oct 29, 2026, 10:45 PM EDT
Completed Phase 1 Interventional

Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma

NCT01665183
View directory record Official record
Conditions
Cutaneous Melanoma, Uveal Melanoma, Ovarian Carcinoma or Other Advanced Solid Tumors
Interventions
ADI-PEG 20
Drug
Lead sponsor
Polaris Group
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2016 · Synced Oct 29, 2026, 10:45 PM EDT
Withdrawn Phase 1 Interventional

Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses

NCT02087813
View directory record Official record
Conditions
Neuromyelitis Optica
Interventions
Alpha1-antitrypsin, methylprednisolone
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2019 · Synced Oct 29, 2026, 10:45 PM EDT
Completed Phase 2 Interventional Results available

6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients

NCT00504660
View directory record Official record
Conditions
Anaplastic Glioma of Brain, Glioblastoma Multiforme, Brain Cancer
Interventions
Capecitabine, Celecoxib (Celebrex), Temozolomide, Lomustine, 6-Thioguanine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2012 · Synced Oct 29, 2026, 10:45 PM EDT
Terminated Phase 1 Interventional

Chemotherapy Plus Bone Marrow Transplantation in Treating Patients With Metastatic Melanoma

NCT00003060
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
filgrastim, busulfan, cyclophosphamide, cyclosporine, methotrexate, allogeneic bone marrow transplantation
Biological · Drug · Procedure
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
16 Years to 44 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Oct 29, 2026, 10:45 PM EDT
Recruiting No phase listed Observational

Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients

NCT06199713
View directory record Official record
Conditions
Melanoma, Melanoma Stage III, Melanoma Stage IV, Unresectable Melanoma
Interventions
18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography
Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 29, 2026, 10:45 PM EDT
Completed Phase 1 Interventional

Fludarabine Followed By Adoptive Immunotherapy in Treating Patients With Stage IV Melanoma

NCT00317759
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
therapeutic autologous lymphocytes, fludarabine phosphate
Biological · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Oct 29, 2026, 10:45 PM EDT
Completed No phase listed Observational

The Registry of Oncology Outcomes Associated With Testing and Treatment

NCT04028479
View directory record Official record
Conditions
Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer, Brain Tumor, Glioblastoma, Astrocytoma, Bile Duct Cancer, Cholangiocarcinoma, Bladder Cancer, Bone Cancer, Synovial Sarcoma, Chondrosarcoma, Liposarcoma, Sarcoma, Kaposi, Sarcoma,Soft Tissue, Sarcoma, Osteosarcoma, CNS Cancer, Brain Stem Neoplasms, Breast Cancer, Cervical Cancer, Colorectal Cancer, Rectal Cancer, Colon Cancer, Esophageal Cancer, Esophagus Cancer, Cancer of Colon, Pancreatic Cancer, Cancer of Pancreas, Testis Cancer, Testicular Cancer, Ureter Cancer, Renal Cell Carcinoma, Kidney Cancer, Gestational Trophoblastic Tumor, Head and Neck Neoplasms, Parotid Tumor, Larynx Cancer, Tongue Cancer, Pharynx Cancer, Salivary Gland Cancer, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Multiple Myeloma, Non Hodgkin Lymphoma, Carcinoid Tumor, Lung Cancer, Neuroendocrine Tumors, Mesothelioma, Thyroid Cancer, Parathyroid Neoplasms, Adrenal Cancer, Small Bowel Cancer, Stomach Cancer, Liver Cancer, Hepatic Cancer, Melanoma, Skin Cancer, Unknown Primary Tumors, Uterine Cancer, Fallopian Tube Cancer, Ovarian Cancer, Prostate Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Waldenstrom Macroglobulinemia, Cancer, Advanced, Thymus Cancer, Nasopharyngeal Carcinoma, Multiple Endocrine Neoplasia, Pheochromocytoma, Small Cell Carcinoma, Pulmonary Carcinoma
Interventions
Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
Diagnostic Test · Drug · Other
Lead sponsor
Taproot Health
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Idaho Falls, Idaho • Laredo, Texas
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 29, 2026, 10:45 PM EDT
Completed Phase 2 Interventional Results available

Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma

NCT00665470
View directory record Official record
Conditions
Skin Cancer, Metastatic Melanoma
Interventions
Aldesleukin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Oct 29, 2026, 10:45 PM EDT
Withdrawn Not applicable Interventional

Standardized Protocol of Surgery and Radiation for Patients With Brain Metastases in Relapsed Neuroblastoma

NCT03406273
View directory record Official record
Conditions
Relapsed Neuroblastoma
Interventions
Cerebral Spinal (CS) radiation, Focal radiotherapy (SRS)
Radiation
Lead sponsor
Giselle Sholler
Other
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 29, 2026, 10:45 PM EDT
Active, not recruiting Phase 4 Interventional

GammaTile and Stupp in Newly Diagnosed GBM

NCT05342883
View directory record Official record
Conditions
Glioblastoma
Interventions
Surgical tumor resection, GammaTile radiation therapy implantation, Stupp protocol (EBRT and Temozolamide)
Device
Lead sponsor
GT Medical Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
16
States / cities
Scottsdale, Arizona • Los Angeles, California • Sacramento, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 29, 2026, 10:45 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Systematically Assessing Changes in Plexiform Neurofibroma Related Disfigurement From Photographs of Subjects With Neurofibromatosis Type 1 on a Phase 2 Clinical Trial

NCT04879160
View directory record Official record
Conditions
Neurofibromatosis 1
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
7 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Oct 29, 2026, 10:45 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Genetic Studies of Strabismus, Congenital Cranial Dysinnervation Disorders (CCDDs), and Their Associated Anomalies

NCT03059420
View directory record Official record
Conditions
Congenital Fibrosis of Extraocular Muscles, Duane Retraction Syndrome, Duane Radial Ray Syndrome, Mobius Syndrome, Brown Syndrome, Marcus Gunn Syndrome, Strabismus Congenital, Horizontal Gaze Palsy, Horizontal Gaze Palsy With Progressive Scoliosis, Facial Palsy, Facial Paresis, Hereditary, Congenital, Third Nerve Palsy, Fourth Nerve Palsy, Sixth Nerve Palsy, Synkinesis, Ocular Motility Disorders, Levator-Medial Rectus Synkinesis, Athabaskan Brainstem Dysgenesis, Tongue Paralysis, Ninth Nerve Disorder, Fifth Nerve Palsy, Seventh Nerve Palsy, Eleventh Nerve Disorder, Twelfth Nerve Disorder, Vagus Nerve Paralysis, Moebius Sequence
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Day and older
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 29, 2026, 10:45 PM EDT
Completed Phase 2 Interventional

Ibuprofen Plus Acetaminophen Versus Oxycodone Alone After Hand Surgery

NCT03111186
View directory record Official record
Conditions
Carpal Tunnel Syndrome, Dupuytren Contracture, Trigger Digit, Ganglion Cysts, De Quervain Disease
Interventions
Oxycodone Hcl 5Mg, Ibuprofen 400 mg, Acetaminophen 650 mg
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Oct 29, 2026, 10:45 PM EDT
Completed Phase 1 Interventional Results available

Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma

NCT01462773
View directory record Official record
Conditions
Melanoma
Interventions
Bortezomib, Interferon Alfa-2b
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 13, 2015 · Synced Oct 29, 2026, 10:45 PM EDT
Completed Not applicable Interventional Results available

Targeted Melanoma Detection With Skin Self-Examination During COVID-19 Restricted Physician Access

NCT04420273
View directory record Official record
Conditions
Melanoma
Interventions
SSE educational intervention, Active control:Healthy Living
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 29, 2026, 10:45 PM EDT
Completed Not applicable Interventional

Feasibility of Olive Oil for Reducing Facial Pain of Trigeminal Neuralgia

NCT05032573
View directory record Official record
Conditions
Trigeminal Neuralgia
Interventions
Olive oil and Dietary Guideline recommendations, Dietary Guideline recommendations
Dietary Supplement · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Oct 29, 2026, 10:45 PM EDT
Terminated Phase 3 Interventional Results available

Cryoablation or External-Beam Radiation Therapy in Treating Patients With Painful Bone Metastases

NCT00540969
View directory record Official record
Conditions
Kidney Cancer, Melanoma (Skin), Metastatic Cancer, Pain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
cryosurgery, radiation therapy
Procedure · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
7
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Jacksonville, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2018 · Synced Oct 29, 2026, 10:45 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)

NCT04660539
View directory record Official record
Conditions
Neuromyelitis Optica Spectrum Disorder
Interventions
satralizumab, azathioprine (AZA), mycophenolate mofetil (MMF), oral corticosteroids
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
13
States / cities
Birmingham, Alabama • Miami, Florida • Columbus, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 29, 2026, 10:45 PM EDT
Recruiting Phase 1 Interventional

Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors

NCT06500819
View directory record Official record
Conditions
Neuroblastoma, Sarcoma, Osteosarcoma
Interventions
B7-H3CART Dose (Intravenous)
Drug
Lead sponsor
Stanford University
Other
Eligibility
2 Years to 30 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 29, 2026, 10:45 PM EDT
Active, not recruiting No phase listed Observational

Post-Authorization Long-Term Safety Study of LUTATHERA

NCT03691064
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
LUTATHERA
Drug
Lead sponsor
Advanced Accelerator Applications
Industry
Eligibility
18 Years and older
Enrollment
1,014 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
4
States / cities
Phoenix, Arizona • Portland, Ohio • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 29, 2026, 10:45 PM EDT
Not listed Phase 2 Interventional

131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma

NCT00114309
View directory record Official record
Conditions
Malignant Glioma, Glioblastoma Multiforme, GBM, Anaplastic Astrocytoma, Oligo-Astrocytoma, Gliosarcoma
Interventions
131-I-TM-601, 131I-TM601
Drug
Lead sponsor
TransMolecular
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2009 · Synced Oct 29, 2026, 10:45 PM EDT
Not listed Not applicable Interventional

Indwelling Interscalene Nerve Catheters in Surgical Management of Idiopathic Adhesive Capsulitis

NCT01606332
View directory record Official record
Conditions
Frozen Shoulder
Interventions
Interscalene block with nerve catheter
Procedure
Lead sponsor
OAD Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Warrenville, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 11, 2013 · Synced Oct 29, 2026, 10:45 PM EDT
Completed Phase 1 Interventional

Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma

NCT00613054
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Zactima, Gleevec, Hydroxyurea
Drug
Lead sponsor
Annick Desjardins
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Oct 29, 2026, 10:45 PM EDT